Danske Bank A S boosted its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 1,955.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,363,909 shares of the biotechnology company's stock after purchasing an additional 1,297,544 shares during the period. Biogen comprises 0.6% of Danske Bank A S's portfolio, making the stock its 26th largest holding. Danske Bank A S owned about 0.92% of Biogen worth $308,080,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Dogwood Wealth Management LLC increased its position in Biogen by 47,400.0% in the third quarter. Dogwood Wealth Management LLC now owns 950 shares of the biotechnology company's stock worth $215,000 after buying an additional 948 shares in the last quarter. Financial Freedom LLC bought a new stake in Biogen in the 3rd quarter valued at $34,000. Moors & Cabot Inc. lifted its position in shares of Biogen by 4.3% in the third quarter. Moors & Cabot Inc. now owns 1,729 shares of the biotechnology company's stock worth $391,000 after buying an additional 71 shares in the last quarter. Citizens & Northern Corp boosted its position in shares of Biogen by 33.2% during the 3rd quarter. Citizens & Northern Corp now owns 9,249 shares of the biotechnology company's stock valued at $2,089,000 after acquiring an additional 2,306 shares during the last quarter. Finally, Allworth Financial LP grew its stake in shares of Biogen by 2,155.5% in the 3rd quarter. Allworth Financial LP now owns 181,185 shares of the biotechnology company's stock worth $40,926,000 after buying an additional 173,152 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company's stock.
Biogen Stock Up 1.2%
Shares of BIIB stock traded up $2.92 during mid-day trading on Friday, hitting $253.40. The stock had a trading volume of 1,028,905 shares, compared to its average volume of 1,250,373. Biogen Inc. has a 12-month low of $160.36 and a 12-month high of $261.00. The firm has a market capitalization of $37.46 billion, a P/E ratio of 108.29, a price-to-earnings-growth ratio of 2.84 and a beta of 0.10. The firm's 50-day moving average is $233.35 and its two-hundred day moving average is $205.04. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.95 and a quick ratio of 1.37.
Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, topping the consensus estimate of $1.99 by $0.63. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The firm had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.63 billion. During the same quarter in the previous year, the business posted $4.81 EPS. Biogen's revenue was up 10.6% on a year-over-year basis. On average, analysts predict that Biogen Inc. will post 12.46 earnings per share for the current fiscal year.
Analyst Ratings Changes
BIIB has been the topic of several recent research reports. Guggenheim upped their target price on shares of Biogen from $280.00 to $300.00 and gave the company a "buy" rating in a research report on Monday, November 2nd. Mizuho lifted their price target on Biogen from $221.00 to $241.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 4th. Wedbush lifted their price target on Biogen from $212.00 to $225.00 and gave the stock a "neutral" rating in a research report on Thursday, October 29th. Citigroup reissued a "neutral" rating on shares of Biogen in a research note on Wednesday, October 28th. Finally, Truist Financial restated a "buy" rating and set a $260.00 price objective (up from $235.00) on shares of Biogen in a research report on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $254.41.
View Our Latest Stock Analysis on BIIB
About Biogen
(
Free Report)
Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy and Friedreich's ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich's ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer's disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Biogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.
While Biogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.